Skip to main content
Explore URMC


Head and Neck Cancer: Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)

Research Question:
What is the safety, tolerability and anti-tumor activity of the research study drug pembrolizumab (MK-3475) in combination with chemoradiation (CRT) to placebo in combination with CRT in subjects with locally advanced head and neck squamous cell carcinoma?

Basic Study Information

You will be assigned to one of two possible study drug treatments: pembrolizumab or placebo in addition to chemoradiation. you have a 1 in 2 chance of getting placebo, neither you or your study doctor will know which of these you are receiving.

Location: Cancer Center
Study Web URL:
Study Reference #: IHAN17023

Lead Researcher (Principal Investigator)

Lead Researcher: Ronald Maggiore

Study Contact Information

Study Coordinator: Park Bogan
Phone: (585) 276-4415

Additional Study Details

Learn More About These Conditions

More information about Carcinoma, Squamous Cell

Return to Search